SINGAPORE — [September 10, 2026] – NIPRO CORPORATION, a global healthcare and medical technology company, today announced the establishment of its Asia Pacific Regional Headquarters (RHQ) in Singapore through the incorporation of NIPRO Asia Pacific Group (NAPG). Supported by the Singapore Economic Development Board (EDB), the RHQ will serve as the strategic hub for NIPRO’s operations across more than 20 markets in the Asia Pacific region. Guided by the principle of “Make it Happen by One NIPRO,” the RHQ brings NIPRO’s regional functions together under a single, coordinated structure.
The establishment of the RHQ is driven by a clear operational need: to bring NIPRO’s regional functions closer together, enabling faster decisions, stronger governance, and more consistent execution across Asia Pacific. Healthcare systems in the region are managing rising demand and increasingly complex care requirements. Addressing these realities effectively requires a regional structure that can respond with speed and clarity.
The RHQ meets this need by uniting NIPRO’s Manufacturing, Sales, iMEP, and Hemodialysis (HD) Centers under a single regional alliance — the “One NIPRO” model. Aligned with NIPRO’s new President and CxO leadership direction, this structure places accountability and coordination closer to the markets NIPRO serves. Centralized resource management for group companies further strengthens operational alignment across the region. The result is a NIPRO that is better positioned to support healthcare professionals and patients across more than 20 Asia Pacific markets with greater consistency and purpose. The RHQ plans to create high-value regional functions such as legal and compliance, regulatory affairs, HR, marketing, IT, finance, and corporate strategy.
NIPRO has maintained a presence in Singapore since 1997. Over nearly three decades, Singapore has served as a trusted gateway connecting NIPRO to customers, healthcare providers, and partners throughout the region. Ahead of the 30th anniversary of NIPRO Asia in 2027, the RHQ represents a new milestone in that continuing relationship and a lasting commitment to serving patients and customers across Asia Pacific.
NIPRO joins a growing concentration of regional headquarters for medical technology companies in Singapore, contributing to a rich ecosystem of regional talent and leadership across industries. The RHQ reflects NIPRO’s strong financial and operational commitment to Singapore. By anchoring regional leadership functions locally, NIPRO strengthens both its own regional capabilities and Singapore’s position as a base for healthcare innovation and talent.
“As NIPRO continues its growth to create a new normal in healthcare in the Asia Pacific region, the establishment of our Regional Headquarters in Singapore represents an impressive milestone in the region,” said Tsuyoshi Yamazaki, President and CEO of NIPRO CORPORATION. “Singapore’s strategic location, world-class infrastructure, strong talent ecosystem, and reputation as a healthcare innovation hub make it an ideal base to further expand our presence across the Asia Pacific region.”
“We welcome NIPRO’s decision to deepen its presence in Singapore through the setting up of its Asia Pacific regional headquarters here, reflecting our position as a leading hub for MedTech companies. We look forward to partnering with NIPRO in its next phase of expansion, in creating opportunities for local talent and delivering impactful healthcare solutions across the region.” said Marcus Dass, Senior Vice President and Head, Global Enterprises, EDB.
About NIPRO CORPORATION
NIPRO is a global healthcare company committed to improving patient outcomes through medical technologies, pharmaceutical solutions, PharmaPackaging, and regenerative medicine. Guided by its promise of helping people live longer and better lives, NIPRO partners with healthcare professionals around the world to deliver safe, reliable, and practical solutions that advance patient care.
Nipro Asia visits St Luke’s ElderCare Active Ageing Centre (Care) @ Northshore
On 21 July 2025, our NIPRO team had the pleasure of visiting St Luke’s ElderCare Active Ageing Centre (Care) @ Northshore as part of our Corporate Social Responsibility (CSR) efforts.
This visit was more than a gesture, it was a meaningful opportunity for us to connect with the community, understand the needs of our seniors, and show appreciation for the dedicated caregivers who support them every day, upholding our Sanpo Yoshi spirit.
We were warmly welcomed by the staff and residents, and it was truly humbling to witness the care, patience, and love that fills the centre. From engaging conversations with the seniors to painting the tote bag with them, each moment underscored the importance of compassion and dignity in eldercare.
As a company that values social impact, NIPRO believes in giving back to the community and supporting those who have contributed so much throughout their lives. Our visit to St Luke’s ElderCare not only deepened our understanding of the challenges in eldercare but also inspired us to continue fostering a culture of empathy and service within our organization.
We extend our sincere gratitude to St Luke’s ElderCare for the opportunity to visit, and we look forward to exploring future collaborations that can bring lasting benefits to the residents and the wider community.
We are pleased to announce the successful installation of the FIRST Makoto Imaging system & Dualpro NIRS+IVUS catheter at University Medical Centre (UMC) Hospital, in Ho Chi Minh City, opening a new chapter in the diagnosis and treatment of cardiovascular diseases!
Congratulations to Dr Vu Hoang Vu, Head of Interventional Cardiology and Dr Tran Hoa, Deputy Head of Interventional Cardiology and all supporting cathlab team for this remarkable milestone! UMC is one of the most advanced IVUS centres in Vietnam, and we are proud to be a part of this moment.
“Thank you to Ms Tram Vy and the vascular team to leading the way in introducing Makoto in Vietnam. Special thanks to Ms Sally Wong and Mr Mahendra Gunatilleke and Mr Cuong Vo for their guidance, system installation and support for a successful first launch. This would not have been possible without the support and collaboration between our local and regional teams,” added Pham Nguyen Nhu Y, General Director of NIPRO Sales Vietnam.
We look forward to celebrating more milestones in Vietnam, advancing healthcare innovation through optimizing clinical decision-making, and empowering cardiologists with better tools for patients.
NIPRO is pleased to announce the successful launch of the Makoto Intravascular Imaging System with the Dualpro IVUS+NIRS catheter at Thong Nhat Hospital, Ho Chi Minh City on 29 July 2025.
Our sincere appreciation goes to A/Prof. Nguyen Van Tan, MD, PhD, Head of Emergency and Interventional Cardiology, for his leadership, along with Dr. Phan Van Truc and the dedicated Cath Lab team, for driving this milestone forward.
This marks a major step in advancing the treatment of calcified and lipid-rich coronary artery disease, optimizing PCI. By integrating Intravascular Ultrasound (IVUS) and Near-Infrared Spectroscopy (NIRS) in a single catheter, the Makoto system provides detailed vessel imaging and precise lipid core plaque (LCP) detection, critical for identifying vulnerable, high-risk lesions.
With next-generation resolution in bandwidth and enhanced lesion crossing capabilities, this powerful tool enhances procedural strategy and supports better outcomes in complex coronary interventions.
We are pleased to share the successful completion of the first few cases using the integrated Makoto NIRS-IVUS system at Gleneagles Jerudong Park Medical Centre (GJPMC) in Brunei!
Congratulation to GJPMC under the leadership of Dr Peter Tay, CEO, and Cardiovascular Laboratory Team (CVL) and management team!
The cases were led by the team under Dr. Billal Patel, Head of Department, Cardiovascular Laboratory Team (CVL), with valuable contributions from Dr. Paula Mota, Dr. Rajinikanth Rajagopal, and the dedicated CVL nursing team.
Makoto NIRS-IVUS MC10i Dual Modality System is optimal for advanced imaging, clinical decision-making, and clinical outcome, successfully installed in GJPMC for better patient outcomes, offering comprehensive insights with both plaque composition (NIRS) and structural vessel data (IVUS). The system is fully integrated, provides seamless workflow efficiency with centralized control from main angio console and touch screen panel for measurements to optimise Percutaneous Coronary Intervention (PCI) outcome.
“We are proud to integrate the first ever Makoto NIRS-IVUS MC10i Dual Modality System. Our appreciation goes to our team with our distributor Parvati, Mr Leigh Childs, Ms Sally Wong , and Mr Hemant Punjabi, Ms Mia Baharin on the successful installation to advance better outcomes for patients in Brunei.” – Seigo Tsuchiya, Managing Director of Nipro Asia.
This achievement marks a significant milestone in advancing intravascular imaging capabilities in the region. We extend our sincere appreciation to the entire clinical team for their insightful feedback and shared experience during the installation and initial use of the system.
This collaboration has been instrumental in optimizing treatment strategies and enhancing risk prediction, ultimately aiming to improve outcomes for cardiac patients in Brunei.
What a time to be alive! ✨
We have successfully unveiled Surdial fleX for the first time in Asia – a new level of support for dialysis care, where Ease meets Expertise for better patient care and operational needs!
Thank you everyone who joined us at the 8th Congress of APSDA in conjunction with PIT PERNEFRI, from 10-12 October 2024 at Bali International Convention Center.
Highlights of the conference include the hands-on workshop jointly organised by our very own iMEP team on Tunneled Catheter and Temporary Catheter Double Lumen Insertion, as well as scientific sessions by esteemed speakers from Indonesia and Thailand.
Stay tuned for more updates on our breakthrough in dialysis care and see you at the next event!
Congress website: https://www.apsda-pernefri2024.com/
Nipro was honoured to participate in the 38th Annual Congress of the Malaysian Society of Nephrology at the Kuala Lumpur Convention Centre – a platform to showcase Nipro’s advancements in renal care.
A heartfelt THANK YOU to Dr. Behram Ali Khan for the Ignite Session on Expanded Hemodialysis (HDx): Dialysis in Evolution.
This moment belongs to all of us and represents our shared values of Live Longer, Live Better.
Together, we will continue to set the gold standard in healthcare and drive advancements that benefit patients, partners, and nephrologists.
AICT-AsiaPCR is one of the world’s leading conferences in interventional cardiovascular medicine that focuses on training and education. Nipro’s vascular team from Japan, South East Asia, and India landed in Singapore for AsiaPCR 2023 – one of the biggest stages for the vascular sector.
Key facts and figures
- 700+ participants
- 5 session rooms covering all the hot topics
- Sponsored Programme
- 330+ Faculty & Presenters
- 6 LIVE Cases sessions
- 396 submissions received
- 18 topics
- 13 supporting Industry Partners
- Up to 11 CME credits
The unique event held in Singapore provided an ideal setting for us to meet with distributors, prospective clients, and potential partners. This setting facilitated conversations about the most recent advancements in intracoronary imaging, particular makoto intravascular imaging system and what lies ahead in the coming year.
Date: 21 – 22 September 2023
Venue: SUNTEC Convention and Exhibition Center. 1 Raffles Boulevard Singapore 039593
Come visit Nipro’s booth A09 at AICT-AsiaPCR 2023 in Singapore.
Congress information: https://www.pcronline.com/Courses/AICT-AsiaPCR
17th September is also known as “World Patient Safety Day”
World Patient Safety Day 2023 is dedicated to the theme “Engaging patients for patient safety” and the slogan “Elevate the voice of patients!” Nipro wishes to initiate this discussion, shedding light on the protection of both patients and healthcare professionals (HCPs).
A SKILL TO BE DEVELOPED
Patient safety is essential for providing high-quality healthcare services, but it is a skill that needs honing. As healthcare facilities have become more complex, patient safety has evolved as a discipline. The rise in accidental harm to patients and HCPs, often due to errors, has prompted efforts to protect and reduce the risks and errors within healthcare settings.
Central to patient safety is PREVENTION:
- Awareness: Includes risk assessment, continuous training and evaluations, and hands-on clinical education.
- Systems: Encompasses policies, procedures, audits, and leadership support.
- Products: Involves aseptic kits, safety devices, and built-in safety mechanisms.
Nipro specifically wants to address the importance of the last point.
GETTING TO THE HEART OF PATIENT SAFETY
Needlestick injuries (NSIs), where individuals are inadvertently pierced by needles or other sharp objects, can lead to exposure to blood or other bodily fluids. This is a grave matter, as unsafe injection practices and accidental punctures can transmit infections such as HIV, Hepatitis B or C, posing a direct threat to patients, HCPs, and waste management professionals, among others. In essence, anyone exposed to the needle is at risk, from its administration to its disposal.
Each year, patients and HCPs suffer from needlestick and sharps injuries, with predictions that 1 in 10 healthcare professionals will be exposed to bloodborne pathogens in the coming year. The World Health Organization estimates that 3 out of 35 million HCPs worldwide face exposure to bloodborne pathogens each year due to these needlestick injuries.
In fact, NSIs are responsible for a significant burden of harm, estimated at 9.2 million years of life lost to disability and death worldwide, referred to as Disability Adjusted Life Years (DALYs).
Furthermore, the CDC estimates that 5.6 million workers in the healthcare industry and related fields are at risk of occupational exposure to bloodborne pathogens. Needlestick injuries during routine occupational duties in 2010 accounted for roughly 40% of hepatitis B and hepatitis C infections, as well as 4.4% of HIV infections in healthcare workers.
The repercussions of an NSI are far-reaching:
- Biological consequences
- Psychological impact
- Documentation and potential investigations
- Follow-up medical examinations
- Time expended
- Additional costs
All of these ultimately place added pressure and stress on healthcare professionals and facilities.
WITH NIPRO, SAFETY COMES FIRST
While Nipro maintains an ongoing commitment to enhancing patient care year-round, this serves as an ideal opportunity to emphasize the importance of ensuring treatment safety and effectiveness for everyone, every day.
To ensure optimal treatment and instill confidence in end-users as HCPs care for patients daily, Nipro’s SafeTouch® line, featuring an irreversible safety mechanism, are designed to offer three critical benefits:
- Maximizing user safety
- Minimizing patient discomfort
- Enhancing ease of use
NIPRO’S PLEDGE AS YOUR BRIDGE BETWEEN PATIENT AND CARE
Whether you’re a dialysis nurse, waste management professional, hospital administrator, or procurement manager, rest assured that Nipro can provide you with the tools to reduce risks and prioritize safety for everyone involved.